Interview with Gabor Somlyai, Managing Director, HYD LLC.
You founded HYD almost 20 years ago, in 1992. Can you first explain to our readers why you made the switch from doing research at the Hungarian Institute of Oncology…
Address: Fürj u. 2. , Budapest, H-1124 Budapest,Hungary
Tel: +36 1 381 0765
Web: http://www.hyd.hu/
HYD LLC. for Cancer Research and Drug Development was established for the research, development and worldwide marketing of pharmaceutical and consumer products based on the proprietary procedure, deuterium depletion, primarily for the prevention and treatment of various kinds of cancer and for exploration of new indication fields for the application of deuterium-depleted water (DDW). Different applications of deuterium depletion are protected by international patents.
In the early nineties, Hungarian molecular biologist, Gábor Somlyai, PhD recognized that the shortage of deuterium can cause significant changes in living organisms. The most important outcome of his research carried out with deuterium-depleted water (DDW) was that tumor cells proved to be extremely sensitive to the withdrawal of deuterium (D). Deuterium depletion is a completely original approach to inhibit the growth of cancer cells in the body and according to the latest results it can also influence other physiological processes like glucose metabolism.
Recently, pharmacological industry started to develop and commercialize deuterium-containing medicines. Strategic replacement of hydrogen atoms in therapeutics with deuterium could positively influence efficacy and side effect profiles of drugs.
HYD’s approach to deuterium depletion of water and other molecules has broad potential to enhance the effectiveness of the presently available oncotherapies and result in innovative new medicines and consumer products for the treatment and prevention of cancer and other (e.g. metabolic) diseases.
HYD LLC. is marketing and distributing several products with decreased deuterium content in food and medicinal product categories. For human consumption Preventa® deuterium-depleted carbonated drinking water brand is available with different D-contents. Considering the D concentration of natural waters (140-150 ppm at our latitude), Preventa® products’ deuterium concentration varies between 125 and 45 ppm as it is indicated on the label. The products are mainly targeted on tumorous patients under conventional treatments or in remission and health-conscious consumers mostly in the age group over 40. It is made of deuterium-depleted water, natural mineral water and carbon dioxide. Preventa® is a registered trademark of HYD LLC.
VETERA-DDW-25® is medicinal preparation for veterinary use for the adjuvant therapy of neoplastic diseases of household pets. This first deuterium-depleted drug was registered in 1999. The active agent is deuterium-depleted water (DDW; 25 ppm D). Vetera-DDW-25® is mostly applied to dogs and cats suffering from cancer.
Several editions of the book „Defeating cancer!” written by Gábor Somlyai PhD are available in different languages and can be ordered from the Hungarian and foreign publishers.
You founded HYD almost 20 years ago, in 1992. Can you first explain to our readers why you made the switch from doing research at the Hungarian Institute of Oncology…
MD Pál Szamosújvari, Judit Jávor, Pál Szamosújvari Jr—Founder, R&D Director, and Director of Pharma Patent respectively—share their insights on the activities of the company, the importance of R&D, the challenges…
Csilla Léka, general manager of Global Clinical Trials in Hungary shares her insights on the portfolio of the company, the most prevalent therapeutic areas, the developments in clinical trials over…
Calin Galaseanu, recently appointed general manager of Novo Nordisk Hungary, elaborates on the country’s strong treatment paradigm for diabetes. He goes on to highlight Hungary’s key positioning as a strategic…
László Dene, managing director of Bellis, gives his insights on the trends affecting the wholesale supply chain and product delivery in Hungary, the strategic positioning of the company as the…
Gergely Jánoki CEO of Medi-Radiopharma shares his insights on the activities of the company, the trends in the radiopharmaceutical industry while highlighting regulatory trends, the importance of quality, the driving…
Dr Antal Feller, CEO of Hungaropharma, gives his insights on the pharma trends affecting the wholesale supply chain and product delivery in Hungary, the strategic positioning of the company, on…
Francesco Banchi, general manager of Boehringer Ingelheim Hungary, elaborates on the successful development of the affiliate in recent years, making progress in new product reimbursement. As an experienced leader in…
Dr. Bodoky Gyorgy, founder and Honorary President of the Hungarian Society of Clinical Oncology (MKOT), explains the activities of the society, the multi-stakeholder collaborations MKOT has, the challenges of oncological…
Péter Ferdinandy and Zsuzsanna Helyes, President and Secretary General of the Hungarian Society for Experimental and Clinical Pharmacology (HUPHAR), share their insights about the role of the society, the R&D…
József Béres, President of Béres and Ferenc Major, CEO, share their insights on the history of the company, its performance and approach to creating brand awareness, the importance of R&D…
Dr. András Szabó, CEO of Szinapszis, a Hungarian market research and consulting agency specialized in the health industry, offers his expert insights on the key challenges and trends shaping the…
After years of planning and collaboration with various stakeholders, in 2017 the Hungarian government launched the Electronic Health Service Area (EESZT): a centralized database of patient records and health interventions…
See our Cookie Privacy Policy Here